The new Axiom 384HT format addresses a current market need by providing scientists with a very economical method of quickly genotyping samples across up to 50,000 markers. Scientists can transfer content from Axiom 96-layout arrays used in sequencing validation and GWAS studies to Axiom 384-layout arrays with 100% fidelity and functionality. The high-throughput assay combined with the Axiom software for automated genotype calling in diploid and complex polyploid species offers an elegant and superior platform for routine genotyping applications.As scientists make progress in decoding the genomes of various human disease states, they can advance their research and commercial objectives by translating those discoveries into applications for routine human disease screening using custom arrays in the 384-layout. Researchers designing custom genotyping arrays receive design support and expertise from Affymetrix’ team of bioinformatics scientists to ensure streamlined SNP selection and intelligently designed arrays that fulfill the specific objectives of their study. The Axiom genotyping platform is the only platform that offers the capability to genotype 384 samples across 50,000 markers simultaneously and affordably genotype large sample collections quickly. To learn more about Axiom ® Genotyping Solutions, please visit http://www.affymetrix.com/axiom for applications in human diseases research and www.affymetrix.com/agrigenotyping for applications in agrigenomics. PLEASE NOTE: Affymetrix ®, the Affymetrix logo, Axiom ®, GeneTitan ® and all other trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners. Products mentioned in this release are for research use only. Not for diagnostic procedures. SOURCE: Affymetrix, Inc. Forward-looking statements All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2012, and other SEC reports for subsequent quarterly periods.
About AffymetrixAffymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. We strive to provide leadership and support, partnering with our customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest for answers toward using biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing our technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.